Short antithrombotic therapy after stent implantation in high bleeding risk patients

Implantation Of Biofreedom® drug-coated stents with very short dual antiplatelet therapy In patients at high bleeding risk: real-world data

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN65588717

Enrollment

100

Registered

2018-12-18

Start date

2015-10-01

Completion date

Unknown

Last updated

2021-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with coronary artery disease and indication for PCI Circulatory System Atherosclerotic heart disease

Interventions

Short antiplatelet therapy after implantation of the Biofreedom DE-stent in a real world scenario All patients will be contacted once in the follow-up period. Adverse events for both

Sponsors

University Hospital of Muenster

Lead Sponsor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Implantation of at least one Biofreedom® stent for the treatment of significant CAD during the study period 2. At least one criterion for high risk bleeding

Exclusion criteria

Exclusion criteria: 1. Aged <18 years 2. Current pregnancy 3. Underlying malignant disease 4. Active bleeding 5. Unable to give informed consent

Design outcomes

Primary

Measure	Time frame
1. Safety of a short antithrombotic therapy after stent implantation, measured using a standardized questionnaire at a single follow-up timepoint 2. Efficacy of short antithrombotic therapy, measured using a standardized questionnaire at a single follow-up timepoint	—

Secondary

Measure	Time frame
Risk factors for events (bleeding or thrombotic), measured using a standardized questionnaire at a single follow-up timepoint	—

Countries

Germany

Contacts

Public ContactDieter Fischer

dieterfischer@yahoo.de+49 (0)1737175707

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026